Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silibinin for Genotype 4 Chronic Hepatitis C
NCT01871662Phase 3Withdrawn
- Sponsor
- Rottapharm Biotech
- Start
- Aug 2013
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Legalon SIL in Chronic Hepatitis C Genotype 4 (3 arms), sponsored by Rottapharm Biotech. Primary endpoint: Undetectable HCV-RNA at 24 Weeks After the end of the Study Treatment. Planned start Aug 2013; status: withdrawn.
02
Drugs
Legalon SIL
03
Conditions
Chronic Hepatitis C Genotype 4
Beyond the preview
Go deeper on NCT01871662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871662.